Division of General Thoracic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Expert Rev Respir Med. 2010 Aug;4(4):499-508. doi: 10.1586/ers.10.40.
Genomic technology continues to advance, and data derived from non-small-cell lung cancer (NSCLC) tumor specimens in conjunction with clinical information are accumulating at an exponential rate. Application of this information to clinical practice for the treatment of patients with NSCLC lags behind the promise of individualized patient management based on genomic medicine. Testing treatment decisions based on genomic information in cancer clinical trials is only now being addressed. How best to incorporate the myriad of potentially available molecular diagnostics into treatment algorithms is not yet clear. Many hurdles and much work remain for the development of true, individualized treatment strategies for NSCLC based on molecular staging. Here we review some of the successes, frustrations and obstacles that exist to further progress in the field.
基因组技术不断进步,与非小细胞肺癌 (NSCLC) 肿瘤标本相关的临床信息呈指数级增长。然而,将这些信息应用于 NSCLC 患者的临床实践以实现个体化患者管理的前景却落后于基于基因组医学的治疗承诺。目前才开始在癌症临床试验中根据基因组信息来测试治疗决策。如何最好地将无数潜在的分子诊断方法纳入治疗算法尚不清楚。基于分子分期为 NSCLC 制定真正的个体化治疗策略仍有许多障碍和工作要做。在这里,我们回顾了该领域进一步发展所存在的一些成功、挫折和障碍。